WallStSmart

Boston Scientific Corp (BSX)vsOrthopediatrics Corp (KIDS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 8373% more annual revenue ($20.61B vs $243.30M). BSX leads profitability with a 17.3% profit margin vs -16.3%. BSX earns a higher WallStSmart Score of 76/100 (B+).

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 6.3
Piotroski: 5/9

KIDS

Hold

38

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: 1.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-29.4%)

Margin of Safety

-29.4%

Fair Value

$37.35

Current Price

$48.55

$11.20 premium

UndervaluedFair: $37.35Overvalued
KIDSUndervalued (+72.6%)

Margin of Safety

+72.6%

Fair Value

$62.94

Current Price

$16.92

$46.02 discount

UndervaluedFair: $62.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$70.87B9/10

Large-cap with strong market position

PEG RatioValuation
0.588/10

Growing faster than its price suggests

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

KIDS1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

KIDS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$472.22M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-11.7%2/10

ROE of -11.7% — below average capital efficiency

Free Cash FlowQuality
$-5.05M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : KIDS

The strongest argument for KIDS centers on Price/Book. Revenue growth of 13.3% demonstrates continued momentum.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : KIDS

The primary concerns for KIDS are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BSX profiles as a mature stock while KIDS is a turnaround play — different risk/reward profiles.

KIDS carries more volatility with a beta of 1.01 — expect wider price swings.

KIDS is growing revenue faster at 13.3% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 38/100), backed by strong 17.3% margins and 11.6% revenue growth. KIDS offers better value entry with a 72.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Orthopediatrics Corp

HEALTHCARE · MEDICAL DEVICES · USA

OrthoPediatrics Corp. The company is headquartered in Warsaw, Indiana.

Want to dig deeper into these stocks?